Showing results (1-10 of 316) with videos related to
Sort By:
Pageof 32
Cancer Investigation|June 24, 2011
A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinomaJohn D Hainsworth, Jeffrey R Infante, David R Spigel, et al.Cancer Chemotherapy and Pharmacology|August 2, 2012
A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumorsSuzanne F Jones, Jeffrey R Infante, Dana S Thompson, et al.Investigational New Drugs|May 2, 2012
Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of METJeffrey R Infante, Terence Rugg, Michael Gordon, et al.The Oncologist|August 28, 2010
A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignanciesHoward A Burris, Jeffrey R Infante, Roxanne C Jewell, et al.Seminars in Oncology|April 28, 2006
Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care?Howard A BurrisThe Oncologist|May 28, 2004
Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinibHoward A BurrisCancer Chemotherapy and Pharmacology|February 5, 2013
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathwayHoward A BurrisExpert Opinion on Biological Therapy|April 22, 2011
Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancerHoward A BurrisAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Trastuzumab Emtansine (T-DM1): Hitching a Ride on a Therapeutic AntibodyHoward A BurrisPageof 32